The news of HC Wainwright & Co. analyst reiterating a Buy rating on Belite Bio and lowering the price target from $58 to $55 may not have a significant short-term impact on the stock price. However, it indicates that the analyst still has a positive outlook on the company, which could be beneficial for investors in the long run.